Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Fragile X Tremor/Ataxia Syndrome
Interventions
DRUG

citocoline

Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.

Trial Locations (1)

60612

Rush University Medical Center, Chicago

All Listed Sponsors
lead

Rush University Medical Center

OTHER

NCT02197104 - Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome | Biotech Hunter | Biotech Hunter